
Promising viral gene therapy for genetic kidney disease
UK resesearchers have engineered an adeno-associated virus vector to treat the heriditary steroid-resistant nephrotic syndrome in children, which is...

Valneva announces extension of existing loan agreement
An add-on loan provides Valneva SE with immediate access to $50m, with an additional $50m available in Q4/2023. According to the vaccine maker, the...

Biomethane fuel offers negative carbon footprint
German scientists at the University of Hohenheim have reported that fuels made from agricultural residues can even have a negative CO2 impact on bus...

UK invests in biopharma manufacturers
The agency announced that seventeen new projects will receive funding for cutting edge medicine manufacturing, delivered by the Innovate UK...

Austrian Kern Tec raises €12m in Series A financing
Food tech specialist Kern Tec GmbH (Vienna) will use €12m from a €12m Series financing to scale up manufacturing of dairy products from upcycled...

Nanobiotix SA licences NBTXR3 to J&J
NBTXR3 is currently being evaluated across different solid tumour indications including NANORAY‑312, a global Phase III pivotal study in ...

BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Under the licence agreement, BenevolentAI will identify and develop new compounds against three targets provided by Merck through hit identification...